News
@BharatBiotech Updates BBV154 Has Received Approval for Phase 3 ... - Latest Tweet by DD News
The latest Tweet by DD News states, '@BharatBiotech Updates BBV154 has received approval for phase 3 clinical trials. The trials will evaluate BBV154 nasal vaccine for both the 2 dose primary schedule and booster dose schedule. #COVIDVaccine@tapasjournalist'
@BharatBiotech Updates
BBV154 (Nasal COVID vaccine) has received approval for phase 3 clinical trials.
The trials will evaluate BBV154 nasal vaccine for both the 2 dose primary schedule and booster dose schedule. #COVIDVaccine@tapasjournalist— DD News (@DDNewslive) January 28, 2022
(The above story first appeared on LatestLY on Jan 28, 2022 03:20 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
